natgillin/translations-raw huggingface dataset:
A suitable daily dose of salmeterol, or salt or thereof, particularly as salmeterol xinafoate, for inhalation may be from 10 to 300 ug, generally from 25 to 200 ug, preferably from 50 to 200 ug, for instance from 50 to 100 ug. 
Prikladna dnevna doza salmeterola, ili njegove soli, osobito salmeterolksinafoata za inhaliranje, može biti od 10 do 300 ug, općenito od 25 do 200 ug, prvenstveno od 50 do 200 ug, na primjer od 50 do 100 ug.
In the foregoing method, the magnetic plate (2) and the additional magnet (3, 3 a, 3 b) are preferably arranged so as to produce a magnetic field having an angle of less than 45° to the plane of the said relief surface in at least one surface area not carrying relief. 
Postupak sukladno patentnom zahtjevu 13, naznačen time, da su magnetska ploča (2) i dodatni magnet (3, 34, 3b) postavljeni tako da stvaraju magnetsko polje s kutem manjim od 45 * u odnosu na ravninu navedene reljefne površine na najmanje jednom području površine bez reljefa, gravura ili ureza.
A compound of formula (II), or a pharmaceutically acceptable salt thereof, Or a tautomeric form thereof wherein: 
Spoj formule (II) ili njegova farmaceutski prihvatljiva sol, [image] ili njegov tautomerni obliknaznačen time da:
In some embodiments, one or more non-naturally encoded amino acids are incorporated in one or more of the following positions in any of the relaxin or prorelaxin polypeptides: B chain positions 5, 7 (SEQ ID NO: 5 or 6 or the corresponding amino acid positions in SEQ ID NOs: 1, 2, 3) and A chain positions 1, 5, 2, 13, 18 (SEQ ID NO: 4 or the corresponding amino acid positions in SEQ ID NOs: 1, 2, 3) and the non-naturally encoded amino acid is linked to a water soluble polymer. 
(a) polipeptid relaksina sadrži polipeptid A lanaca relaksina sa SEQ ID NO: 4 i polipeptid B lanca relaksina sa SEQ ID NO: 5 ili SEQ ID NO: 6 supstituiran sa ne-prirodno kodiranom aminokiselinom na poziciji odabranoj iz grupe koja se sastoji od: ostatka 1 lanca A, ostatka 5 lanca A, ostatka 13 lanca A, ostatka18 lanca A, i ostatka 7 lanca B; 1 (b) ne-prirodno kodirana aminokiselina je para-acetil-fenilalanin koja je po izboru povezana sa veznikom, polimerom, polimerom topivim u vodi, ili biološki aktivnim molekulom.
The method of claim 2, wherein the AN count is reduced by at least 50% reduction in the subject relative to baseline AN count. 
Anti-TNFa protutijelo za uporabu prema zahtjevu 2, naznačeno time, da se broj AN smanjuje za najmanje 50% kod subjekta u odnosu na početni broj AN.
A compound comprising a modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 549, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides; 
Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 16 vezanih nukleozida koji imaju nukleobaznu sekvencu koja obuhvaća sekvencu koja je navedena u SEQ ID NO: 549, pri čemu modificiran oligonukleotid obuhvaća: segment razmaka koji se sastoji od deset vezanih deoksinukleozida;
ZC sequence number inside CoMP set setting section 102 sets a ZC sequence number for an SRS, that is, the number to be used by all cells forming a CoMP set where a plurality of CoMP terminals present in a cell belong, and outputs the setting result to hopping pattern calculation section 104 . 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 2, naznačen time da je CoMP set konfiguriran od strane svih ćelija koje konfiguriraju CoMP setove kojima pripada pluralitet CoMP terminala prisutnih u ćelijama.
Qingdainone can be in an amount of 0.1-5% (w/w) of the refined extract, for example, 0.1-1%, 0.1-5%, 0.5-1%, or 0.5-5% (w/w) of the refined extract. 
Rafinirani ekstrakt u skladu s bilo kojim od patentnih zahtjeva 4 do 8, naznačen time što su dvoje ili više od indirubina, indiga, triptantrina i kingdainona kao komponenata, u količini od 90 % - 99 % (tež./tež.) rafiniranog ekstrakta.
Process according to claim 1, wherein said aldehyde-releasing biocide and/or biocide with one or more aldehyde groups and said soluble lithium compound are added separately to the aqueous preparation. 
Uporaba prema zahtjevu 1, naznačena time da je vodeni pripravak disperzija ili suspenzija prirodnog kalcijevog karbonata, sintetskog, istaloženog kalcijevog karbonata, kaolina, talka, aluminijevog hidroksida, aluminijevog silikata, titanijevog dioksida ili njihovih smjesa, punila ili pigmenata.
Figure 4 shows the illustration presented in Figure 3 in a second (sampling) position; 
Slika 4 - prikazuje napravu koja je prikazana ne slici 3 u drugom položaju (uzimanje uzorka);
a container (1) configured to store a tissue sample (45); said container (1) comprising a bottom (13); 
posudu (1) prilagođenu za prihvaćanje i čuvanje uzorka (45) tkiva; gdje navedena posuda (1) sadrži dno -
the variable heavy chain comprises the variable heavy chain framework sequence from IGHV1-f and the CDRs from the VH chain of murine antibody HP1/2, wherein CDR1 comprises the sequence GFNIKDTYM, CDR2 comprises the sequence RIDPASGDTKYDPKFQV and CDR3 comprises the sequence GMWVSTGYALDF, and amino acid residues at framework positions 24 and 94 of the variable heavy chain according to the Kabat numbering scheme are substituted, wherein the substituted residue at framework position 24 is alanine (A) and the substituted residue at framework position 94 is aspartic acid (D); 
aminokiselinski ostatci na okvirnim pozicijama 1, 67 i 87 od varijabilnog slabog lanca prema shemi numeriranja Kabat, supstituirani s ne-humanim ostatcima, dok ne-humani ostatak na okvirnoj poziciji 1 je serin (S), ne-humani ostatak na okvirnoj poziciji 67 je tirozin (Y) i ne-humani ostatak na okvirnoj poziciji 87 je fenilalanin (F); i
The pharmaceutical kit according to claim 16, wherein the containers are connectable through a connector device. 
Farmaceutski komplet u skladu sa zahtjevom 14 pri čemu se spremnici mogu spojiti kroz uređaj za spajanje.
Process according to claim 1, in which in stage a), a vapor explosion of the biomass is carried out by exerting compression and then carrying out pressure relief of the biomass mixed with water and an acid compound. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time što se u stupnju a), eksplozija pare biomase provodi kompresijom i zatim provođenjem rasterećenja tlaka biomase pomiješane s vodom i kiselim spojem.
A pharmaceutical composition which comprises a sodium channel blocker selected from the group consisting of lamotrigine and crobenetine in combination with a selective serotonin uptake inhibitor selected from the group consisting of fluoxetine, paroxetine, sertraline, escitalopram and citalopram. 
Farmaceutski sastav koji sadrži natrijev blokator kanala izabran iz skupine koja je sastavljena od lamotrigina i krobenetina u kombinaciji sa selektivnim inhibitorom unosa serotonina izabranog iz skupine koja se sastoji od fluoksetina, paroksetina, sertralina, escitaloprama 1 citaloprama. 2.
The compounds of formula (I) wherein R3 is hydrogen, said compounds being represented by (I-1), can also be prepared by removal of a protecting group PG, from a corresponding nitrogen-protected intermediate (3a), as in the following reaction scheme. 
(d) priprema spoja formule (I) pri čemu R* je vodik, a navedeni spoj je prikazan sa (1-1), iz odgovarajućeg dušikovog-zaštićenog intermedijera (32), pri čemu PG predstavlja skupinu koja štiti dušik: AN
A chimeric peptide consisting of a first domain, a second domain and optionally a linker sequence, the first domain consisting of a trafficking sequence and the second domain consisting of a JNK inhibitor sequence, wherein the first domain consists of the all-D retro-inverso amino acid sequence according to SEQ ID NO:6 and wherein the second domain consists of the all-D retro-inverso amino acid sequence according to SEQ ID NO:2, wherein the first domain is linked to the C-terminal end of the second domain either directly or by said linker sequence consisting of 1 to 10 amino acids. 
JNK inhibicijska sekvenca prema bilo kojem zahtjevu od 1 do 4, naznačena time, da JNK inhibicijska sekvenca mijenja učinak JNK kada je navedeni peptid prisutan u stanici koja eksprimira JNK. Kimerni peptid, naznačen time, da se sastoji od prve domene i druge domene koje su povezane kovalentnom vezom, pri čemu prva domena sadrži transportnu sekvencu, a druga sadrži JNK inhibicijsku sekvencu prema bilo kojim od zahtjeva od 1-5, gdje je prva domena vezana na C-terminalni kraj druge domene.
The boom mountable robotic arm of claim 4 wherein said at least one hinge means includes a hinge plate having a fastener for securing said hinge plate in an operating position in which said at least one electrically insulated support post extends perpendicularly away from said upper beam assembly. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 2, naznačena time, da navedena zglobna šarka uključuje zglobnu pločicu koja ima pričvršćivač za osiguranje navedenih barem jedne zglobne pločice u radnom položaju u kojem se navedeni električno izolirani podupirači protežu pod pravim kutom dalje od navedenog gornjeg grednog sklopa.
The preparation according to claim 7, characterised by that said other polysaccharide is carboxymethyl cellulose having the molecular weight within the range from 1 000 to 1 500 000 g/mol and the substitution degree within the range from 0.1 to 3 expressed as the total number of carboxymethyl groups to the total number of monosaccharidic units, and being in its free form or in the form of a pharmacologically suitable salt which is a sodium, potassium, lithium, calcium, magnesium, zinc, cobalt, manganese or another salt or a mixture thereof. 
Pripravak prema zahtjevu 7, naznačen time da je navedeni drugi polisaharid karboksimetil celuloza koja ima molekularnu težinu u rasponu od 1 000 do 1 500 000 g/mol i stupanj supstitucije u rasponu od 0.1 do 3 izraženo kao ukupan broj karboksimetilnih skupina prema ukupnom broju monosaharidnih jedinica, te je u slobodnom obliku ili u obliku farmakološki pogodne soli koja je natrijeva, kalijeva, litijeva, kalcijeva, magnezijeva, cinkova, kobaltova, sol mangana ili druga sol ili njihova smjesa.
The compound or method according to claim 6 or 8, wherein the compound according to claim 1 is administered in combination with a further therapeutic agent. 
Sol spoja za uporabu prema patentnom zahtjevu 5, pri čemu se sol spoja prema patentnom zahtjevu 1 administrira u kombinaciji sa dodatnim terapeutskim sredstvom.
The method according to any of claims 1 to 7, wherein the level of methylated genomic DNA is measured for SEPTIN9 (SEQ ID NO: 1) and optionally for RASSF2a (SEQ ID NO: 16), and wherein the methylated genomic DNA or fragment is measured by MethyLight™, HeavyMethylTM or methylation specific PCR. 
Metoda u skladu sa bilo kojim od patentnih zahtjeva 1 do 7, gdje je nivo metilirane genomske DNK izmjeren za SEPTIN9 (SEK ID BR: 1) i izborno za RASSF2a (SEK ID BR: 16), i gdje je metilirana genomska DNK ili fragment izmjeren pomoću MethyLight™, HeavyMethylTM ili specifičnim PCR-om za metilaciju.
There were added 25 g per minute. 
Dodaje se 25 g u minuti.
a second waterproofing layer 19 for the inner face 17 of the hollow structure 16, 
- drugi vodootporni sloj (19) za navedeni unutarnji dio (17) navedene šuplje strukture (16).
a channel on a surface of the intermediate frustum shaped insulating layer, positioned adjacent to the second conductive layer, 
kanal (404) na površini srednjeg izolacijskog sloja, smješten pored drugog vodljivog sloja,
applying a solution comprising poly (ethylene glycol) having a concentration of about 10% by weight and sorbitol having a concentration of from 5% to 20% by weight to the cation exchange chromatographic material, thereby separating the antibody of the IgG class in monomeric form with reduced host cell protein content from the antibody in aggregate form and obtaining the antibody in monomeric form with reduced host cell protein content. 
- proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IeG- razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % 1 sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
The method of claim 5, wherein the obtaining comprises using the AISB in obtaining the one or more AIBV indications in the one or more AIBVs. 
Postupak sukladno Zahtjevu 5, postupak nadalje koristi AISB za dobivanje jedne ili više indikacija AIBV u jednom ili više AIBV.
an element drive (230) adapted to provide a movement of said elongated element between said retracted position in a second rotational position of said drum and an advanced position in a first rotational position of said drum, said second rotational position being different from said first rotational position of said drum, 
- pogon (230) elementa prilagođen da omogući pogon navedenog elementa između navedenog uvučenog položaja u drugom rotacijskom položaju navedenog bubnja i isturenog položaja u prvom ili trećem rotacijskom položaju navedenog bubnja,
A process according to any one of the claims 1 to 14, characterised in that said open-cell foam has a density of less than 60 kg/m3, preferably of less than 50 kg/m3 and more preferably of less than 40 kg/m3. 
Postupak prema jednom od zahtjeva 1 do 13, naznačen time da staničnootvorena pjenasta tvar pokazuje gustoću manju od 60 kg/m3.
imprinting a lens pattern (5,27) into the protective layer (4) overlying the image in the image area (Ai) while in its liquid or softened state by contacting the protective layer with a transparent and flexible imprint member (16,20) that is provided with the pattern, 
utiskivanja uzorka leća (5,27) u zaštitni sloj (4) koji prekriva sliku u područje za sliku (Ai) dok je u tekućem ili omekšanom stanju stavljanjem u kontakt zaštitnog sloja s prozirnim i fleksibilnim elementom za utiskivanje (16,20) kojem se dodaje uzorak, -
Use of a compound or a pharmaceutically acceptable salt thereof, according to claim 13, wherein the compound is 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. 
Spoj prema zahtjevu 7, naznačen time, da je to: 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-(3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegova farmaceutski prihvatljiva sol.
The method of claim 4, wherein the monoclonal antibody is a human, humanized or chimeric antibody or comprises an antigen-binding fragment thereof. 
Sastav iz patentnog zahtjeva 24, pri čemu je navedeno terapijsko protutijelo ljudsko, humanizirano ili kimerično protutijelo ili sadrži njegov antigen vezujući fragment.
The composition for use according to any one of Claims 1 to 13, wherein the HIF-1a 4-prolyl hydroxylase inhibitor is a salt comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 10 do 14, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, brain tumors, gliomas, benign tumour of the skin (e.g. 
fibrosarkoma i rabdomiosarkoma), melanoma, teratokarcinoma, neuroblastoma, tumora mozga, glioma, benignog tumora kože (npr.
heating and pressurising the reactor(s) by the supply of steam, 
zagrijavanje i stlačivanje u reaktoru dovođenjem pare,
at least 11 % of the cells in the population express detectable levels of CD289 (Toll-like receptor 9), 
(iv) najmanje 11 % stanica u populaciji na svojoj površini izražava uočljive razine CD289 (receptor 9 tipa Toll),
Holding assembly for gem positioning, said assembly being formed by a system for fastening gems to a watch dial according to claim 1 and by a lower body (25) for supporting and holding the plate-shaped elements (23, 24), such body being provided, at the position of the gems on the dial, with cavities (36) having a concave bottom, designed to form a seat for receiving a part of the gem body arranged below the dial (13). 
Držaći sklop za smještavanje dragulja, gdje je navedemi sklop načinjen od sustava za pričvršćivanje dragulja na brojčanik ručnog sata u skladu s patentnim zahtjevom 1 i donjeg tijela (25) koje nosi i drži pločaste elemente (23, 24), gdje takvo tijelo ima, na položaju za dragulje na brojčaniku, šupljine (36) s udubljenim dnom, dizajnirane da tvore sjedište za prihvat dijela tijela dragulja koji se nalazi ispod brojčanika (13).
A pharmaceutical composition comprising the immunoconjugate of any one of claims 1 to 18 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća imunokonjugat prema bilo kojem od zahtjeva 1 do 215i farmaceutski prihvatljiv nosač.
A combination according to claim 1 or 2, wherein the long-acting B2 agonist is selected from the group comprising formoterol, salmeterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. A combination according to claim 3, wherein the long-acting B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija prema zahtjevu 1 ili 2, naznačena time, da je 2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuterol, klenbuterol, dopeksamin, fenoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)- formoterol, reproterol, ritodrin, rimoterol, salbutamol, sibenadet, sulfonterol, terbutalin i tulobuterol, po izboru u obliku njihovih racemata, njihovih enantiomera, njihovih diastereomera i njihovih smjesa, te prema potrebi njihovih farmakološki kompatibilnih kiselinskih adicijskih soli.
at least one heavy chain variable region, said heavy chain variable region comprising: 
najmanje jednu varijabilnu regiju lakog lanca, spomenuta varijabilna regija lakog lanca obuhvaća:
a heavy chain variable region CDR1 of SEQ ID NO: 14; a heavy chain variable region CDR2 of SEQ ID NO: 28; a heavy chain variable region CDR3 of SEQ ID NO: 42; a light chain variable region CDR1 of SEQ ID NO: 56; a light chain variable region CDR2 of SEQ ID NO: 70; and a light chain variable region CDR3 of SEQ ID NO: 84. 
(n) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 14; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 28; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 42; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 56; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 70; 1 CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 84.
A cylinder lock as defined in claim 3, wherein said integral key sensing part with said projecting key code contact surfaces (220 a, 221 a) is disposed on a finger (219) which extends transversely from said body part (217). 
Cilindar brava kako je definirano u zahtjevu 22, naznačena time da je navedeni integralni dio za raspoznavanje ključa sa navedene barem dvije susjedne izbočene stopice (220a, 221a) raspoređen na izbočini (219) koja se proteže poprečno od navedenog dijela kućišta (217).
A 5 mm long carbon felt substrate, cut from rayon carbon felt sold by Fiber Materials, Inc., was butted against the fuel source. 
5 mm dug supstrat od ugljične klobučine, isječen 1z rejonske ugljične klobučine koju prodaje Fiber Materials, Inc., stavi se da dodiruje izvor goriva.
and the combined aqueous basic extract washed with ethyl acetate (2 1. 
i spojeni vodeni bazni ekstrakt se ispere sa etilacetatom (2 1.
The sustained release aminopyridine composition of claim 1, wherein said composition is for increasing muscle strength in a patent with multiple sclerosis and wherein said composition Is administered as a stable dose treatment. 
Kompozicija aminopiridina sa produženim oslobađanjem za poboljšanje mišićnog tonusa donjih ekstremiteta kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
or a pharmaceutically acceptable salt thereof; wherein: L is selected from the group consisting of NH, CH2, S and O; 
Spoj prema formuli (I) [image] gdje L je odabran od skupine koja se sastoji od NH, CH2, S i O;
The mixture was filtered through Celite, evaporated and the residue dissolved in ethyl acetate (300ml) washed with water (2x100ml), saturated sodium bicarbonate solution (2x100ml) and brine (100ml) and then passed through a hydrophobic frit and evaporated. 
Smjesu se filtrira kroz Celite, te otpari, a ostatak otopi u etil-acetatu (300 ml), ispere vodom (2 x 100 ml), zasićenom otopinom natrijevog bikarbonata (2 x 100 ml) i slanom vodom (100 ml), propusti kroz hidrofobnu fritu, te otpari.
One or more chelating agents can optionally be included in the sunscreen in amounts ranging from about 0.001 to about 0.5 weight percent preferably about 0.01 % weight percent. 
Po potrebi se može uključiti jedno ili više sredstava za keliranje u sredstvo za zaštitu od sunca u količinama koje se kreću od oko 0,001 do oko 0,5 masenih postotaka, poželjno oko 0,01 % masenih postotaka.
A cell culture medium comprising a basal medium for animal or human cells to which is added: Epidermal Growth Factor, an FGF able to bind to FGFR2 or FGFR4, preferably FGF10 as a mitogenic growth factors, Nicotinamide, and preferably, a Wnt agonist, preferably R-spondin 1 and/or Wnt-3a. 
Medij stanične kulture koji obuhvaća osnovni medij za životinjske ili humane stanice u koji se dodaje: EGF, FGF koji se može vezati za FGFR2 ili FGFR4, Nikotinamid, Wnt agonist izabran iz R-spondin 1, R-spondin 2, Rspondin 3 i R-spondin 4.
The formulation of claim 1, wherein the concentration of propylene glycol is about 5.0% w/w and the ratio of water to propylene glycol in the formulation ranges from 12:1 to 18:1. 
Vodena formulacija sukladno patentnom zahtjevu 1 pri čemu je odnos vode prema propilen glikolu u toj formulaciji barem 20:1 (w/w).
or a pharmaceutically acceptable addition salt or enantiomer thereof. The method of claim 2, wherein said compound is selected from the group consisting of: 
instrukcija za uporabu farmaceutskog pripravka iz (a) za liječenje stanja koje je odabrano iz skupine koju čine:
A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3:1-5:1) or a mixed solvent of isopropyl alcohol and water (volume ratio = 9:1-10:1). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo miješano otapalo s-butil alkohola i vode (omjer volumena = 3:1-5:1) ili miješano otapalo izopropil alkohola i vode (omjer volumena = 9:1- .
In the case of a hyperglycemic disorder (e.g., diabetes, insulin resistance, glucose intolerance, metabolic syndrome, etc.), for example, an improvement can be a lowering or a reduction in blood glucose, a reduction in insulin resistance, a reduction in glucagon, an improvement in glucose tolerance, or glucose metabolism or homeostasis. 
Himerni peptid definiran u bilo kojem od zahtjeva 1 do 9, naznačen time da se upotrebljava u postupku liječenja poremećaja, pri čemu je poremećaj hiperglikemijsko stanje, inzulinska rezistencija, hiperinsulinemija, intolerancija na glukozu, metabolički sindrom, pretilost, nepoželjna tjelesna masa, bezalkoholna masnoća bolest jetre (NAFLD), nealkoholni steatohepatitis (NASH) ili ateroskleroza.